Pancreatic neuroendocrine tumours

Overview

Pancreatic neuroendocrine tumours (pNETs), historically referred to as islet cell tumours, represent a distinct and heterogeneous group of neoplasms arising from the neuroendocrine cells scattered throughout the pancreas. Unlike pancreatic adenocarcinoma (exocrine pancreatic cancer), which originates in the ductal cells and carries a notoriously poor prognosis, pNETs arise from the hormone-producing cells of the endocrine pancreas (the Islets of Langerhans).

Although relatively rare—accounting for approximately 3% to 5% of all pancreatic neoplasms—the incidence of pNETs has been rising steadily over the past three decades, largely due to improved cross-sectional imaging (CT/MRI) and increased awareness. The annual incidence is estimated at 1 to 1.5 per 100,000 people, though autopsy studies suggest a much higher prevalence of clinically silent, microscopic tumours.

pNETs exhibit a broad spectrum of biological behaviour, ranging from indolent, slow-growing tumours that may never cause symptoms during a patient’s lifetime, to aggressive, high-grade carcinomas that behave similarly to pancreatic adenocarcinoma. Understanding this spectrum is critical for patients and clinicians alike, as management strategies vary dramatically based on tumour grade, stage, and hormonal functionality.

Anatomy and Cell of Origin: The Neuroendocrine System

To understand pNETs, one must first understand the normal anatomy of the pancreas. The pancreas is a retroperitoneal organ with dual functions:

1. Exocrine Function (95-98% of mass): Acinar cells produce digestive enzymes (amylase, lipase, proteases) secreted into ducts emptying into the duodenum.
2. Endocrine Function (1-2% of mass): Clusters of cells known as the Islets of Langerhans (approx. 1–2 million islets) secrete hormones directly into the bloodstream.

pNETs originate from the five primary cell types within the Islets of Langerhans:

Table 1: Cell types of the Islets of Langerhans and associated hormones.

When these cells undergo neoplastic transformation, they may retain the ability to synthesize and secrete their specific hormones (Functional pNETs) or lose this ability entirely (Non-functional pNETs).

Classification Systems: Grading, Staging, and Functionality

Accurate classification is the cornerstone of prognostication and treatment planning. Three parallel systems are used simultaneously.

1. WHO Grading (2019 Classification) – “How Fast Does It Grow?”

The World Health Organization (WHO) classification relies on mitotic count (mitoses per 2 mm² / 10 high-power fields) and Ki-67 proliferation index (percentage of positively stained nuclei). This determines the grade (aggressiveness).

Critical Distinction: The 2019 WHO update split the old “G3” category into Well-Differentiated NET G3 and Poorly Differentiated Neuroendocrine Carcinoma (NEC)**. This is vital: NET G3 may respond to targeted therapies (e.g., everolimus, sunitinib) or peptide receptor radionuclide therapy (PRRT), whereas NEC is primarily treated with platinum-based chemotherapy (cisplatin/carboplatin + etoposide).

2. TNM Staging (AJCC 8th Edition / UICC) – “How Far Has It Spread?”

Staging assesses anatomical extent.

• T (Primary Tumour):
• T1: ≤ 2 cm (T1a ≤ 0.5 cm; T1b > 0.5–1 cm; T1c > 1–2 cm).
• T2: > 2 cm but ≤ 4 cm.
• T3: > 4 cm or invading duodenum/bile duct.
• T4: Invading adjacent organs (stomach, spleen, colon, major vessels) or major vessels (SMA, SMV, celiac axis, aorta).
• N (Regional Lymph Nodes):
• N0: No regional nodal metastasis.
• N1: Regional nodal metastasis present.
• M (Distant Metastasis):
• M0: No distant metastasis.
• M1: Distant metastasis (liver, peritoneum, bone, lung, etc.).

Stage Grouping:

• Stage I: T1–T2, N0, M0
• Stage II: T3, N0, M0
• Stage III: T4 or N1, M0
• Stage IV: Any T, Any N, M1

3. Functional Classification – “Does It Make Hormones?”

This is often the most clinically apparent classification for patients.

• Functional (Hormonally Active) pNETs (15–30%): Secrete bioactive hormones causing distinct clinical syndromes. Named after the predominant hormone (e.g., Insulinoma, Gastrinoma).
• Non-Functional (NF-pNETs) (70–85%): Do not secrete hormones causing a clinical syndrome. They may secrete inert peptides (like Pancreatic Polypeptide, Chromogranin A, Neuron-Specific Enolase) measurable in blood but asymptomatic. Usually diagnosed at a later stage/larger size due to mass effect or incidental imaging findings.

How Does It Look? (Pathology, Imaging, and Gross Appearance)

Understanding the visual and microscopic characteristics of pNETs helps demystify the diagnostic process. “How does it look” varies depending on whether you are viewing it on a radiology screen, the operating table, or under a microscope.

1. Gross Pathology (Macroscopic Appearance)

Upon surgical resection, pNETs typically present as well-circumscribed, round or ovoid masses. Unlike the rock-hard, infiltrative, grey-white appearance of pancreatic adenocarcinoma, pNETs often have a distinct fibrous capsule (pseudocapsule) separating them from the surrounding pancreatic parenchyma.

• Colour: Classically described as tan-yellow to reddish-brown. The high vascularity often imparts a reddish hue.
• Consistency: Usually firm to rubbery, softer than adenocarcinoma.
• Internal Architecture: On cut section, they are typically solid. However, larger tumours (>3–4 cm), particularly G2/G3 tumours, frequently show cystic degeneration, hemorrhage, or necrosis in the centre.
• Calcification: Psammoma bodies (concentric calcifications) may be visible grossly as gritty white flecks, particularly in insulinomas or metastatic deposits.
• Relationship to Ducts: pNETs arise within the parenchyma, often displacing or compressing the main pancreatic duct (Wirsung’s duct) rather than arising from it. Ductal dilatation upstream of the tumour is a key imaging sign.

Visual Analogy:** If adenocarcinoma looks like a “rock infiltrating butter,” a pNET often looks like a “marble or gumball sitting in the butter,” sometimes with a dark, hemorrhagic center if it has outgrown its blood supply.

2. Microscopic Appearance (Histopathology)

The diagnosis is confirmed by light microscopy and immunohistochemistry (IHC).

Architectural Patterns:

• Organoid/Nesting (Trabecular/Gyriform/Solid): The most common pattern. Cells form nests, ribbons, or rosettes separated by delicate fibrovascular septa (resembling normal islets but larger and more irregular).
• Rosette Formation: Homer-Wright rosettes (cells around a central neuropil) or Flexner-Wintersteiner rosettes (cells around a central lumen) may be seen, highlighting neural differentiation.

Cytological Features (Well-Differentiated NETs G1/G2/G3):

• Monotony: Remarkable uniformity of cells (“monotonous” appearance).
• Nuclei: Round to oval, “Salt-and-Pepper” Chromatin (finely stippled, evenly distributed heterochromatin – the hallmark of neuroendocrine differentiation).
• Nucleoli: Usually inconspicuous or small in G1/G2; may be prominent in NET G3.
• Cytoplasm: Moderate amount, granular, eosinophilic (pink) or clear (due to lipid/glycogen content).
• Mitoses: Rare in G1; countable in G2/G3.
• Necrosis: Absent in G1/G2; may be present in NET G3 (usually focal).

Immunohistochemistry (IHC) Panel – The Diagnostic Gold Standard:

Pathologists use a panel to confirm neuroendocrine lineage and assess grade.

Table 2: Key Immunohistochemical Markers in pNET Diagnosis.

3. Radiological Appearance (Imaging Phenotype)

Imaging is the primary modality for detection, staging, and follow-up.

A. Contrast-Enhanced Multiphasic CT / MRI (The Workhorse)

pNETs are typically hypervascular (arterially enhancing).

• Arterial Phase (Pancreatic Parenchymal Phase ~25-35s post-injection): The tumour enhances vividly and homogeneously (bright white), often brighter than the surrounding pancreatic parenchyma (“light bulb” sign). This is the best phase for detection.
• Venous/Portal Venous Phase (~60-70s): Enhancement fades; tumour becomes isodense or hypodense (washout) relative to the pancreas. Cystic/necrotic areas become apparent as non-enhancing fluid density.
• Delayed Phase: May show persistent enhancement of fibrous stroma or capsule.
• Calcifications: Seen in 20-30% on non-contrast scans; may be coarse, rim, or punctate.
• MRI Specifics:
• T1-weighted: Typically hypointense (darker than pancreas) due to high cellularity; hyperintense if hemorrhagic/proteinaceous cystic content.
• T2-weighted: Hyperintense (bright) relative to pancreas (classic “light bulb” on T2).
• Diffusion Weighted Imaging (DWI): Restricted diffusion (high cellularity) – high signal on high b-value, low ADC values. Helps differentiate from cystic neoplasms (IPMN, SCN).

B. Functional Imaging (Somatostatin Receptor Imaging)

Ga-68 DOTATATE / DOTATOC / DOTANOC PET/CT:** The current gold standard for staging well-differentiated pNETs (G1/G2/NET G3).

• Mechanism: Binds to Somatostatin Receptor Subtype 2 (SSTR2), highly expressed on well-differentiated NET cells.
• Appearance: Intense focal uptake (high Standardized Uptake Value – SUV) at primary tumour and metastatic sites (liver, nodes, bone).
• Superiority: Detects significantly more lesions than CT/MRI alone, particularly small liver metastases, lymph nodes, and bone lesions.
• FDG PET/CT (F-18 Fluorodeoxyglucose): Used primarily for High Grade (G3) / Poorly Differentiated NEC. These tumours lose SSTR expression (low Ga-68 uptake) but gain high glucose metabolism (high FDG uptake). A “flip-flop” phenomenon (Ga-68 negative / FDG positive) signals dedifferentiation.

C. Endoscopic Ultrasound (EUS)

• Appearance: Hypoechoic (dark), well-defined, homogeneous mass arising from the pancreatic parenchyma.
• Utility: Highest sensitivity for small tumours (<1-2 cm); allows Fine Needle Aspiration (FNA) for cytology/grade confirmation before surgery. Doppler shows intratumoral vascularity.

Symptoms: The Clinical Spectrum

Symptoms of pNETs are dichotomous: they result either from hormone hypersecretion (Functional Syndromes) or from mass effect / metastatic burden (Non-Functional).

A. Functional Syndromes (Hormonally Active Tumours)

These tumours secrete biologically active peptides causing specific, often dramatic, clinical constellations. Recognition leads to early diagnosis.

1. Insulinoma (Beta-cell tumour) – The Most Common Functional pNET (~60-70% of functional)

• Mechanism: Autonomous, unregulated insulin secretion → profound hypoglycaemia.
• Whipple’s Triad (Diagnostic Criteria):

1. Symptoms consistent with hypoglycaemia.
2. Low plasma glucose (< 55 mg/dL / 3.0 mmol/L) at time of symptoms.
3. Relief of symptoms upon glucose administration.

• Neuroglycopenic Symptoms (Brain glucose deprivation):
• Confusion, personality change, lethargy, dizziness, blurred/double vision, seizures, coma.
• Often occur fasting (early morning) or post-exercise.
• Adrenergic Symptoms (Catecholamine surge response to low glucose):
• Sweating (diaphoresis), palpitations, tremor, anxiety, hunger, nausea.
• Key Feature: Weight gain (patients eat frequently to abort attacks).
• Demographics: 90% benign, solitary, intrapancreatic, <2 cm; 10% malignant; 5-10% associated with MEN1.

2. Gastrinoma (G-cell tumour / Zollinger-Ellison Syndrome) – 2nd Most Common Functional

• Mechanism: Excess gastrin → massive gastric acid hypersecretion.
• Zollinger-Ellison Syndrome (ZES) Triad:

1. Severe Peptic Ulcer Disease (PUD) – refractory, recurrent, atypical locations (distal duodenum, jejunum).
2. Gastric Hypersecretion (High Basal Acid Output – BAO).
3. Non-beta islet cell tumour (Gastrinoma).

• Symptoms:
• Abdominal pain (epigastric, burning, gnawing) – mimics standard PUD.
• Diarrhoea / Steatorrhoea (Acid inactivates pancreatic lipase & precipitates bile acids → fat malabsorption). Present in 30-50%; may be the ONLY symptom.
• Gastroesophageal Reflux Disease (GERD) – severe, refractory.
• Weight loss (pain/fear of eating/malabsorption).
• Location: “Gastrinoma Triangle” (junction of cystic duct/common bile duct, 2nd/3rd duodenum, neck/body pancreas). 60-90% in duodenum (often small, multiple), not pancreas.
• Malignant Potential: Higher than insulinoma (~60% metastatic at diagnosis). Strong association with MEN1 (20-30%).

3. Glucagonoma (Alpha-cell tumour) – Rare, Usually Malignant at Diagnosis

• Mechanism: Excess glucagon → catabolic state (glycogenolysis, gluconeogenesis, lipolysis).
• Classic Triad (The “4 Ds”):

1. Diabetes Mellitus (Mild to moderate, new onset, often ketosis-resistant).
2. Dermatitis – Necrolytic Migratory Erythema (NME): Pathognomonic. Angiolupoid, migratory, erythematous, blistering, crusting rash in perineum, groin, lower extremities, flexures. Caused by hypoaminoacidemia/zinc deficiency.
3. Deep Vein Thrombosis (DVT) / Pulmonary Embolism (PE): Hypercoagulable state (10-25%).
4. Depression / Neuropsychiatric symptoms.

• Other: Weight loss (catabolism), glossitis/stomatitis (sore tongue/mouth), anemia.
• Prognosis: >80% metastatic (liver) at diagnosis; large tumours (>4-5 cm).

4. VIPoma (Verner-Morrison Syndrome / Pancreatic Cholera) – Rare

• Mechanism: Vasoactive Intestinal Peptide (VIP) → stimulates intestinal cyclic AMP → massive water/electrolyte secretion.
• Hallmark: Profuse, Watery, Secretory Diarrhoea (>1-3 L/day, often >5 L).
• Persists during fasting (distinguishes from osmotic diarrhoea).
• Nocturnal diarrhoea.
• Consequences: Severe hypokalaemia (muscle weakness, ileus, arrhythmias), metabolic acidosis, dehydration, renal failure.
• Associated: Hypochlorhydria/Achlorhydria (VIP inhibits acid), flushing (10%), hyperglycaemia.
• Location: 90% in pancreatic tail/body. 60% metastatic at diagnosis.

5. Somatostatinoma (Delta-cell tumour) – Very Rare

• Mechanism: Somatostatin inhibits everything (insulin, glucagon, gastrin, VIP, CCK, pancreatic exocrine, gallbladder contraction).
• Syndrome (Inhibitory):
• Diabetes Mellitus (insulin suppression).
• Gallstones (stasis due to inhibited contraction).
• Steatorrhoea / Diarrhoea (exocrine inhibition + bile salt deficiency).
• Hypochlorhydria (gastrin inhibition).
• Weight loss, anemia.
• Location: Duodenum > Pancreas (Head). Duodenal ones often smaller, associated with NF1/Von Recklinghausen (psammomatous histology).

6. Other Rare Functional Types

• ACTHoma: Ectopic Cushing’s Syndrome (rapid onset, hypokalaemia, hyperpigmentation).
• GRFoma: Acromegaly (Growth Hormone-Releasing Factor).
• PTHrPoma: Humoral Hypercalcaemia of Malignancy.
• Serotonin-secreting: Carcinoid Syndrome (Flushing, diarrhoea, valvular heart disease) – rare in primary pancreatic origin; usually requires liver mets to bypass portal circulation.

B. Non-Functional pNETs (NF-pNETs) – The Silent Majority (~70-85%)

These tumours cause symptoms solely due to local mass effect or metastatic burden. Because they lack a hormonal “alarm bell,” they are often large (>4 cm) at diagnosis.

Local Mass Effect Symptoms (Depend on Location):

• Head/Uncinate Process:
• Obstructive Jaundice: Painless, progressive yellowing of skin/sclera, dark urine, pale stools, pruritus (compression of Common Bile Duct).
• Gastric Outlet Obstruction: Nausea, vomiting (large food particles), early satiety, weight loss (compression of duodenum).
• Pancreatitis: Recurrent acute pancreatitis (compression of main pancreatic duct).
• Body/Tail:
• Vague Abdominal Pain / Discomfort: Dull, aching, left upper quadrant or epigastric; may radiate to back (retroperitoneal invasion/nerve involvement).
• Palpable Mass: Left upper quadrant fullness.
• Splenic Vein Thrombosis: Tumour invades/compresses splenic vein → Left-sided Portal Hypertension → Isolated Gastric Varices (risk of massive upper GI bleed) + Splenomegaly + Thrombocytopenia. Normal liver function tests distinguish from cirrhosis.
• General Constitutional Symptoms (Advanced Disease):
• Unintentional weight loss (>10% body weight).
• Anorexia / Early satiety.
• Fatigue / Cachexia.
• Carcinoid Syndrome (Late): If bulky liver metastases secrete serotonin directly into systemic circulation (flushing, diarrhoea, wheezing, right heart valvular fibrosis).

Diagnostic Workup: A Stepwise Approach

1. Biochemical Markers (Blood/Urine)

• Chromogranin A (CgA): General NET marker. Sensitivity 60-90%, Specificity high. Elevated in >80% of metastatic pNETs. False positives: Renal failure, PPI use (major), heart failure, inflammatory conditions. Must stop PPIs 2 weeks prior if possible.
• Pancreatic Polypeptide (PP): Often elevated in NF-pNETs; less affected by PPIs.
• Specific Hormone Assays (If Functional Suspected):
• Insulinoma: Fasting Glucose, Insulin, C-peptide, Proinsulin, Beta-hydroxybutyrate, Sulfonylurea screen (72-hr supervised fast gold standard).
• Gastrinoma: Fasting Serum Gastrin (>1000 pg/mL + pH <2 = diagnostic; <1000 = Secretin Stimulation Test).
• VIPoma: Plasma VIP.
• Glucagonoma: Plasma Glucagon.
• Genetic Testing: Recommended for all patients with pNET (NCCN/ENETS guidelines) to screen for MEN1, VHL, NF1, TSC, MUTYH.

2. Cross-Sectional Imaging (Anatomical)

• Triphasic Pancreas Protocol CT (Arterial, Venous, Delayed) OR MRI with MRCP. MRI preferred for liver mets characterization; CT faster/more accessible.

3. Functional Imaging (Receptor-Based)

• Ga-68 DOTATATE PET/CT: Standard for staging well-diff pNETs (G1/G2/NET G3).
• FDG PET/CT: Mandatory for G3 / suspected high-grade transformation.

4. Tissue Confirmation (Histology)

• EUS-FNA: Preferred for pancreatic primary (high yield, low risk). Core biopsy (19G/20G) preferred over FNA for Ki-67 grading accuracy.
• Percutaneous Biopsy: For liver metastases if primary not accessible or to confirm metastatic origin.
• Liquid Biopsy (ctDNA/NETest): Emerging; not yet standard for primary diagnosis but useful for monitoring.

Management Strategies: A Multidisciplinary Approach

Management is highly individualized based on Grade, Stage, Functionality, Symptoms, Performance Status, and Patient Preference. All cases should be discussed at a Neuroendocrine Tumour Multidisciplinary Team (MDT) Meeting.

1. Surgery: The Only Curative Intent

• Resectable Localized Disease (Stage I-III): Surgical Resection is Standard.
• Enucleation: For small (<2 cm), superficial, G1, non-functional / insulinomas away from main duct. Preserves parenchyma.
• Formal Resection (Distal Pancreatectomy ± Splenectomy, Pancreaticoduodenectomy/Whipple, Central Pancreatectomy, Total Pancreatectomy): For tumours >2 cm, G2/G3, near main duct, functional tumours (except insulinoma enucleation), or positive margins suspected. Lymphadenectomy is standard.
• Borderline Resectable / Locally Advanced: Neoadjuvant therapy (PRRT, targeted, chemo) → Reassessment for conversion surgery.
• Metastatic Disease (Stage IV):
• Cytoreductive Surgery (Debulking): If >90% tumour burden resectable (especially liver mets) + low grade (G1/G2) + symptomatic/hormonal control needed. Improves survival and symptom control.
• Palliative Surgery: Biliary bypass (jaundice), gastric bypass (obstruction), splenectomy (splenic vein thrombosis/varices).

2. Medical Therapy (Systemic)

3. Management of Functional Syndromes (Symptom Control)

• Insulinoma: Diazoxide (inhibits insulin release) + Hydrochlorothiazide (prevents fluid retention); SSAs (variable response); Everolimus (off-label); Frequent small meals / Complex carbs / Cornstarch (slow glucose release).
• Gastrinoma/ZES: High-dose Proton Pump Inhibitors (PPIs) (e.g., Omeprazole 40-80mg BID/TID) – Lifelong usually. Monitor B12, Iron, Magnesium, Bone density.
• VIPoma: SSAs (Octreotide) – Dramatic response in >80%. Aggressive IV fluid/electrolyte (K+/Mg2+) replacement.
• Glucagonoma: SSAs (rash/diarrhoea control); Amino acid infusion / Zinc supplementation (for NME); Anticoagulation (prophylactic or therapeutic for DVT); Diabetes management.
• Carcinoid Syndrome (Liver Mets): SSAs (1st line); Telotristat Ethyl (tryptophan hydroxylase inhibitor – reduces serotonin synthesis) for refractory diarrhoea.

4. Surveillance & Follow-Up

No universal consensus; tailored to Grade/Stage/Resection Status.

• Post-Resection (Curative Intent):
• G1: CT/MRI + CgA/PP q 6-12 mo x 10 yrs (late recurrence possible).
• G2: CT/MRI + CgA/PP q 3-6 mo x 5 yrs, then 6-12 mo.
• G3 / NEC: q 3 mo x 2-3 yrs (high early recurrence).
• Metastatic / Unresected: q 3-6 mo imaging (CT/MRI or Ga-68 DOTATATE) + markers. Ga-68 DOTATATE preferred for response assessment in SSTR+ disease (RECIST 1.1 + PERCIST).

Prognosis and Survival

Prognosis is highly variable, primarily driven by Grade (Ki-67) and Stage.

Table 4: Prognostic Estimates (Data derived from SEER, ENETS, NANETS registry studies. Individual outcomes vary significantly.)

Favourable Prognostic Factors: Low Ki-67, R0 resection, absence of necrosis, SSTR2a positivity, ATRX/DAXX intact, Primary in pancreas (vs duodenum for gastrinoma), Low tumour burden.

Unfavourable Factors: High Ki-67, Positive margins (R1/R2), Lymphovascular invasion, Perineural invasion, Necrosis, High tumour burden, Liver metastases >25% replacement, FDG-avidity in well-diff tumour.

Genetic Syndromes: When to Suspect Hereditary Disease

Up to 10-20% of “sporadic” pNETs harbour germline mutations. Genetic counselling and testing (multi-gene panel) are recommended for ALL patients diagnosed with pNET.

Table 5: Major Hereditary Syndromes Associated with pNETs. AD=Autosomal Dominant, AR=Autosomal Recessive.

Living with pNETs: Quality of Life and Supportive Care

A pNET diagnosis is a chronic disease journey for many. Beyond oncology, comprehensive care includes:

1. Nutritional Support:

• Pancreatic Exocrine Insufficiency (PEI): Common post-resection (especially Whipple/Distal Pancreatectomy) or with bulky tumours. Pancreatic Enzyme Replacement Therapy (PERT – Creon, Zenpep, etc.) with meals/snacks is essential. Monitor fat-soluble vitamins (A, D, E, K).
• Diabetes Mellitus: “Pancreatogenic” (Type 3c) Diabetes. Brittle control; requires insulin often; hypoglycaemia risk high if exocrine insufficiency untreated (erratic absorption). Continuous Glucose Monitors (CGM) highly beneficial.
• Post-Prandial Hypoglycaemia (Dumping Syndrome): Post-Whipple. Small frequent meals, low simple carbs, acarbose.

1. Bone Health: SSAs, mTOR inhibitors, and metastatic bone disease increase osteoporosis risk. DEXA scans q 1-2 yrs; Calcium/Vitamin D; Bisphosphonates/Denosumab if indicated.
2. Psychosocial Support: Anxiety, “scanxiety,” chronic fatigue, financial toxicity. Referral to psycho-oncology, social work, patient advocacy groups (see Resources).
3. Fertility & Pregnancy: PRRT, Chemo, Everolimus, Sunitinib are teratogenic. Strict contraception during treatment and washout periods. Fertility preservation discussion before systemic therapy. Pregnancy possible in stable disease off therapy; requires MDT coordination.

Emerging Therapies and Future Directions

The landscape is rapidly evolving.

• Novel PRRT Agents: Ac-225 DOTATATE (Alpha-emitter) – Higher linear energy transfer; promising for refractory/bulky disease or Lu-177 failures. Lu-177 Edotreotide (different chelator).
• Immunotherapy: ICI (Checkpoint Inhibitors – PD-1/PD-L1) generally ineffective in well-differentiated pNETs (cold tumours, low TMB). Active in High-Grade NEC (especially with high TMB/MSI-H). Trials combining ICI + TKI (e.g., Pembrolizumab + Lenvatinib) or ICI + PRRT ongoing.
• Targeted Agents: Surufatinib (VEGFR/FGFR1/CSF-1R inhibitor) – Approved in China for pNET (SANET-p trial); FDA review ongoing. Belzutifan (HIF-2α inhibitor) – Highly active in VHL-associated pNETs (RCC also).
• Cell Therapy: CAR-T targeting SSTR2 or other antigens (early phase).
• Liquid Biopsy: NETest (Multigene PCR blood test) and ctDNA for real-time monitoring of tumour burden and clonal evolution (resistance mutations).

Frequently Asked Questions (FAQ)

Q: Is a pNET “cancer”?

A: Yes, by definition, a neoplasm with metastatic potential is a malignancy (cancer). However, low-grade (G1) pNETs often behave more like a chronic illness than an aggressive cancer. The term “carcinoid” is outdated and misleading for pancreatic primaries; “Pancreatic Neuroendocrine Tumour” or “Pancreatic NET” is the correct terminology.

Q: Can a benign pNET become malignant?

A: Pathologically, “benign” vs “malignant” is determined by the presence of metastasis or invasion, not just histology. A tumour classified as “benign” on a small biopsy cannot be guaranteed not to metastasize later. All pNETs have malignant potential. We use Grade (Ki-67) to estimate this risk.

Q: Do I need to avoid certain foods?

A: Generally, no strict “anti-cancer diet” exists. However:

• Functional tumours: Avoid triggers (e.g., large meals/alcohol for insulinoma; spicy/acidic foods for ZES; high-fat meals if steatorrhea/PEI).
• On SSAs: May cause fat malabsorption → take enzymes with meals.
• General: Balanced Mediterranean-style diet; maintain muscle mass/weight.

Q: Can I drink alcohol?

A: Moderation is key. Alcohol stresses the pancreas (pancreatitis risk) and liver (common metastatic site). Heavy alcohol use is discouraged, especially with liver metastases or on hepatotoxic drugs (Everolimus, Sunitinib, Chemo).

Q: What is the risk to my children/siblings?

A: If you have a germline mutation (MEN1, VHL, etc.), first-degree relatives have a 50% chance of inheriting it. They should be referred for genetic counselling and predictive testing. If your tumour is sporadic (no germline mutation), the risk to relatives is not significantly increased above population risk.

Q: How often do I need scans?

A: It depends entirely on your Grade and Stage.

• Resected G1: Yearly imaging often sufficient after 2-3 years.
• Metastatic G2 on active treatment: Every 3-4 months.
• Stable metastatic disease off treatment: Every 6 months.
• Always: Discuss the radiation risk vs benefit with your oncologist. Ga-68 DOTATATE PET involves radiation but gives superior info; MRI has no radiation.

Summary of Key Takeaways

1. pNETs are distinct from Pancreatic Adenocarcinoma. They arise from hormone cells, are often slower-growing, and have vastly better treatment options and prognosis.
2. Grading (Ki-67) is King. It dictates biology (Indolent vs Aggressive) and therapy choice (Targeted/PRRT vs Chemo). Insist on Ki-67 reporting.
3. Functional vs Non-Functional changes the presentation. Functional tumours present early with hormone syndromes (Hypoglycaemia, Ulcers, Diarrhoea, Rash). Non-functional tumours present late with mass effect (Jaundice, Pain, Weight Loss).
4. Imaging is Specialized. Standard CT misses small lesions. Ga-68 DOTATATE PET/CT is the staging standard for well-differentiated disease.
5. Surgery is Curative for Localized Disease. Enucleation for small/insulinomas; Formal resection for larger/higher grade.
6. Systemic Therapy is Sequenced. SSAs (1st line control) → PRRT / Everolimus / Sunitinib / CAPTEM (2nd line+) based on Grade, SSTR status, and progression.
7. Genetics Matter. Test for MEN1/VHL/NF1/TSC. It changes surveillance for you and saves relatives’ lives.
8. Quality of Life is Manageable. PERT for digestion, PPIs for acid, SSAs for hormones, Bone protection, Psychosocial support.
9. Seek an NET Specialist/MDT. This is a rare disease. Outcomes are significantly better at high-volume centres with dedicated Neuroendocrine Tumour programs.

References

Clinical Practice Guidelines:

• National Comprehensive Cancer Network (NCCN) (2024) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Neuroendocrine and Adrenal Tumors. Version 2.2024. Plymouth Meeting, PA: NCCN. Available at: https://www.nccn.org/ (Accessed: 15 October 2023).
• Falconi, M. et al. (2020) ‘ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Neoplasms and Non-Functional Pancreatic Neuroendocrine Neoplasms’, Neuroendocrinology, 110(5), pp. 411–435. doi: 10.1159/000504624.
• Pavel, M. et al. (2020) ‘ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Follow-up and Documentation’, Neuroendocrinology, 110(5), pp. 463–476. doi: 10.1159/000504626.

Key Textbooks & Reviews:

• Klimstra, D.S., Klöppel, G., La Rosa, S. and Rindi, G. (2019) ‘Classification of Neuroendocrine Neoplasms of the Pancreas and Digestive System’, in WHO Classification of Tumours Editorial Board (ed.) WHO Classification of Tumours: Digestive System Tumours. 5th edn. Lyon: IARC Press, pp. 234–253.
• Strosberg, J.R. (2023) ‘Pancreatic Neuroendocrine Tumors’, in DeVita, V.T., Lawrence, T.S. and Rosenberg, S.A. (eds.) DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology. 12th edn. Philadelphia: Wolters Kluwer.
• Oberg, K. and Castellano, D. (2022) ‘Management of Pancreatic Neuroendocrine Tumors: Current Standards and Future Directions’, Journal of Clinical Oncology, 40(16), pp. 1765–1776. doi: 10.1200/JCO.21.02456.

Landmark Clinical Trials:

• Caplin, M.E. et al. (2014) ‘Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors (CLARINET)’, New England Journal of Medicine, 371(3), pp. 224–233. doi: 10.1056/NEJMoa1316158.
• Raymond, E. et al. (2011) ‘Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors’, New England Journal of Medicine, 364(6), pp. 501–513. doi: 10.1056/NEJMoa1003825.
• Yao, J.C. et al. (2016) ‘Everolimus for Advanced Pancreatic Neuroendocrine Tumors (RADIANT-3)’, New England Journal of Medicine, 368(7), pp. 605–615. doi: 10.1056/NEJMoa1009290.
• Strosberg, J. et al. (2017) ‘Phase 3 Trial of Lu-177-Dotatate for Midgut Neuroendocrine Tumors (NETTER-1)’, New England Journal of Medicine, 376(2), pp. 125–135. doi: 10.1056/NEJMoa1607427. Note: Subgroup analysis confirmed efficacy in pancreatic NET cohort.
• Kunz, P.L. et al. (2021) ‘Capecitabine and Temozolomide (CAPTEM) for Advanced Pancreatic Neuroendocrine Tumors: Long-term Outcomes’, Journal of Clinical Oncology, 39(15_suppl), p. 4075. doi: 10.1200/JCO.2021.39.15_suppl.4075.

Patient Advocacy & Support Organizations:

• Neuroendocrine Tumor Research Foundation (NETRF): https://www.netrf.org/ (Comprehensive patient guides, specialist finder, research updates).
• Carcinoid Cancer Foundation (CCF): https://www.carcinoid.org/ (Education, support groups, physician directory).
• Neuroendocrine Cancer UK (NCUK): https://www.neuroendocrinecancer.org.uk/ (Excellent patient information booklets, nursing support line).
• The Pheo Para Alliance: https://pheopara.org/ (Relevant for MEN1/VHL associated pheo/pNET overlap).
• MEN1 Clinical Guidelines & Support (AMEND): https://www.amend.org.uk/ (Specific for Multiple Endocrine Neoplasia Type 1).

Diagnostic & Monitoring Tools:

• NETest (Wren Laboratories): https://wrenlabs.com/netest/ (Multigene transcriptomic blood test for disease monitoring).
• Gallium-68 DOTATATE PET/CT Locator: https://www.snmmi.org/ClinicalPractice/PET-CT-Center-Locator.aspx (Find centres offering functional imaging).